Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Yukari Suzuki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9625-4616; OpenAlex author ID A5103099241. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 7

  1. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… Co-author DOI 10.1002/deo2.70154↗
  2. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… Co-author DOI 10.1093/jjco/hyaf194↗
  3. Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable … Co-author DOI 10.1002/deo2.70014↗
  4. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1007/s10147-025-02796-0↗
  5. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  6. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  7. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takeshi Okamoto · 4 shared papers, 2025–2026 · strength 1.01
  2. Tsuyoshi Takeda · 4 shared papers, 2025–2026 · strength 1.01
  3. Masato Ozaka · 4 shared papers, 2025–2026 · strength 1.01
  4. Takafumi Mie · 4 shared papers, 2025–2026 · strength 1.01
  5. Takaaki Furukawa · 4 shared papers, 2025–2026 · strength 1.01
  6. Naoki Sasahira · 4 shared papers, 2025–2026 · strength 1.01
  7. Takashi Sasaki · 2 shared papers, 2026 · strength 0.54
  8. Tomotaka Saito · 3 shared papers, 2020–2023 · strength 0.35
  9. Kazunaga Ishigaki · 3 shared papers, 2020–2023 · strength 0.35
  10. Naminatsu Takahara · 3 shared papers, 2020–2023 · strength 0.35
  11. Tsuyoshi Hamada · 3 shared papers, 2020–2023 · strength 0.35
  12. Kei Saito · 3 shared papers, 2020–2023 · strength 0.35
  13. Yousuke Nakai · 3 shared papers, 2020–2023 · strength 0.35
  14. Jun Hamada · 1 shared paper, 2026 · strength 0.26
  15. Hiroki Oyama · 2 shared papers, 2020–2023 · strength 0.25
  16. Suguru Mizuno · 2 shared papers, 2020–2021 · strength 0.20
  17. Hirofumi Kogure · 2 shared papers, 2020–2021 · strength 0.20
  18. Kazuhiko Koike · 2 shared papers, 2020–2021 · strength 0.20
  19. Tatsunori Suzuki · 1 shared paper, 2023 · strength 0.16
  20. Mitsuhiro Fujishiro · 1 shared paper, 2023 · strength 0.16
  21. Hideaki Ijichi · 1 shared paper, 2021 · strength 0.11
  22. Hiroyuki Isayama · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.